Document is current
Any future updates will be listed below
-
Authors
Kraemer, Anne I.
Chong, Chloe
Huber, Florian https://orcid.org/0000-0002-2585-9079
Pak, HuiSong
Stevenson, Brian J.
Müller, Markus
Michaux, Justine
Altimiras, Emma Ricart
Rusakiewicz, Sylvie
Simó-Riudalbas, Laia
Planet, Evarist
Wiznerowicz, Maciej
Dagher, Julien https://orcid.org/0000-0003-3864-5149
Trono, Didier https://orcid.org/0000-0002-3383-0401
Coukos, George https://orcid.org/0000-0001-8813-7367
Tissot, Stephanie
Bassani-Sternberg, Michal https://orcid.org/0000-0002-1934-954X
- License Information
-
More Information
Article History
Received: 27 May 2022
Accepted: 24 March 2023
First Online: 1 May 2023
Competing interests
: In the last 3 years, G.C. has received grants and research support or has been coinvestigator in clinical trials by Bristol-Myers Squibb, Tigen Pharma, Iovance, F. Hoffmann La Roche AG and Boehringer Ingelheim. The Lausanne University Hospital (CHUV) has received honoraria for advisory services that G.C. has provided to Genentech, AstraZeneca AG and EVIR. Patent WO2019086711A1 related to the NeoTIL technology from the Coukos laboratory has been licensed by the Ludwig Institute, also on behalf of the University of Lausanne and the CHUV, to Tigen Pharma. G.C. has previously received royalties from the University of Pennsylvania for CAR-T cell therapy licensed to Novartis and Tmunity Therapeutics. The remaining authors declare no competing interests.
